ARS Pharma to Report Third Quarter 2026 Financial Results
Key Highlights
- ➤ARS Pharma will report third quarter 2026 financial results November 5, 2026
- ➤Conference call and webcast scheduled for 1:30 p.m. PT / 4:30 p.m. ET
- ➤neffy is approved for emergency treatment of Type I allergic reactions
- ➤ARS-2 is in a Phase 2b trial for chronic spontaneous urticaria flares
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to review its third quarter 2026 financial results.
Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company’s website. A replay of the webcast will be available for 30 days following the event.
Get started
Create a free account to read the full story.